2023年第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2~6日举行，一年一度的学术盛宴将启。ASCO官网已公布会议日程和摘要题目。
【肿瘤资讯】特别整理了摘要速递专场（Rapid Abstract Session）、壁报交流专场（Poster Discussion Session）、口头摘要专场（Oral Abstract Session）及临床科学研讨会（Clinical Science Symposium）的免疫治疗研究，与临床医生分享。
摘要速递专场（Rapid Abstract Session）
摘要号：2512
患有自身免疫性疾病或在加入TAIL研究之前接受过抗PD-1治疗的NSCLC患者的自身抗体基线分析
Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study.
讲者：Delvys Rodriguez-Abreu, MD, PhD | Complejo Hospitalario Universitario Insular-Materno Infantil
摘要号：2513
CAR T细胞靶向淋巴恶性肿瘤中的CD47
Targeting CD47 in lymphoid malignancies with CAR T cells.
讲者：Alexander Paul Boardman | Memorial Sloan Kettering Cancer Center
摘要号：2514
常见的遗传性NOD2突变与免疫检查点抑制剂的异常反应有关
Association of common inherited NOD2 mutations with exceptional response to immune checkpoint inhibitors.
讲者：Megan Babette Barnet, PhD, BS, MBBS, FRACP | Garvan Institute of Medical Research
摘要号：2515
免疫检查点抑制剂（ICI）耐药性疾病中的肠道微生物组特征
Intestinal microbiome characterization in immune checkpoint inhibition (ICI) resistant disease.
讲者：Pavlina Spiliopoulou, MD, PhD | Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto
摘要号：2516
UNICANCER SAFIR02-Lung/IFCT1301试验中，使用度伐利尤单抗维持治疗的晚期非小细胞肺癌（NSCLC）患者ctDNA肿瘤分数与生存率的关系
Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.
讲者：Filippo Gustavo Dall'Olio, MD | Cancer Medicine Department, Institut Gustave Roussy
壁报交流专场（Poster Discussion Session）
摘要号：2517 | Poster Bd #: 359
抗CD19异体CAR T ALLO-501/501A治疗复发/难治性大B细胞淋巴瘤（r/r LBCL）的1期结果
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
讲者：Frederick L. Locke, MD | H. Lee Moffitt Cancer Center and Research Institute
摘要号：2518 | Poster Bd #: 360
CLDN6 CAR-T细胞治疗复发/难治性实体瘤±CLDN6编码的mRNA疫苗：使用自动化产品的BNT211-01 1期试验的剂量递增数据
CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.
讲者：John B. A. G. Haanen, MD, PhD | Netherlands Cancer Institute
摘要号：2519 | Poster Bd #: 361
自体TAC01-HER2治疗复发或难治性实体瘤的安全性和有效性的I/II期试验
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
讲者：Benjamin L. Schlechter, MD | DFCI/BWH cancer center
摘要号：2520 | Poster Bd #: 362
一种表达IL-12和PD-1抗体的溶瘤单纯疱疹病毒T3011，通过瘤内注射单药治疗晚期实体瘤——一项1/2a期研究
A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors.
讲者：Dongmei Ji, MD | Fudan University Shanghai Cancer Center（复旦大学附属肿瘤医院 季冬梅）
摘要号：2521 | Poster Bd #: 363
TLR9受体激动剂SD-101和免疫检查点抑制（ICI）压力给药（PEDD）治疗转移到肝脏的葡萄膜黑色素瘤（MUM）的1期PERIO-01试验的安全性和早期生物效应
Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).
讲者：Kamaneh Montazeri, MD | Massachusetts General Hospital
摘要号：2522 | Poster Bd #: 364
激素阳性、HER2阴性乳腺癌的免疫微环境： 聚焦肿瘤浸润淋巴细胞、空间表型和三级淋巴结构
The immune microenvironment in hormone positive, HER2 negative breast cancer: A focus on tumour infiltrating lymphocytes, spatial phenotypes and tertiary lymphoid structures.
讲者：Mairi Lucas, MBChB | St Vincents University Hospital
摘要号：2523 | Poster Bd #: 365
一种靶向TREM1（表达在骨髓细胞上的触发受体1）单克隆抗体PY159的1a期剂量递增研究
A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).
讲者：Ira Seth Winer, MD, PhD | Barbara Ann Karmanos Cancer Institute
摘要号：2524 | Poster Bd #: 366
一种避免肝毒性、用于晚期实体瘤患者的新型CD137激动剂抗体AGEN2373的 1期研究
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.
讲者：Minal A. Barve, MD | Mary Crowley Cancer Research Center
摘要号：2525 | Poster Bd #: 367
LVGN6051 CD137/4-1BB激动性抗体用于晚期实体瘤患者的首次人体1a期剂量研究，无论是否使用帕博利珠单抗
First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.
讲者：Adil Daud, MD | University of California-San Francisco
摘要号：2526 | Poster Bd #: 368
TORC1/2抑制剂onatasertib联合特瑞普利单抗治疗晚期实体瘤患者的1/2期研究
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.
讲者：Pei Shu, PhD | Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University（四川大学华西医院创新药物临床研究与评价重点实验室 Pei Shu）
摘要号：2527 | Poster Bd #: 369
RiMO-301联合姑息性放射治疗晚期肿瘤的1期剂量递增研究
A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.
讲者：Matthew Koshy, MD | University of Chicago
摘要号：2528 | Poster Bd #: 370
AMPLIFY-201，一项针对高复发风险的KRAS G12D或G12R突变胰腺癌和结直肠癌患者的辅助ELI-002 2P免疫疗法的首次人体安全性和有效性试验
AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.
讲者：Eileen Mary O'Reilly, MD | Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College
口头摘要专场（Oral Abstract Session）
摘要号：2501
visugromab（CTL-002）+纳武利尤单抗治疗晚期/转移性抗PD1/L1复发/难治性实体瘤的2A期试验（GDFATHER-TRIAL）的初步结果
Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).
讲者: Ignacio Melero Bermejo, MD, PhD | Laboratory of Immunology, Clinica Universitaria de Navarra
摘要号：2502
免疫调节芳烃受体（AhR）抑制剂BAY2416964在晚期实体肿瘤患者中的首次人体I期研究初步结果
Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.
讲者: Ecaterina Elena Dumbrava, MD | The University of Texas MD Anderson Cancer Center
摘要号：2503
在涉及24个癌种、超过8,000例患者中，基于FDA批准的瘤突变负荷（TMB）检测数据以及单药免疫检查点抑制剂（ICI）的真实世界总生存率（rwOS）
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
讲者: David R. Gandara, MD, FASCO | Division of Hematology/Oncology, Department of Medicine, UC Davis Comprehensive Cancer Center
摘要号：2504
评估接受检查点抑制剂治疗的罕见癌症患者的RECIST肿瘤大小和生存率变化（SWOG S1609）
Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).
讲者: Megan Othus, PhD | Fred Hutchinson Cancer Center
摘要号：2505
晚期实体瘤的ATRC-101 1b期试验的中期更新
Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.
讲者: Bartosz Chmielowski, MD, PhD | University of California Los Angeles, Jonsson Comprehensive Cancer Center
摘要号：2507
PD-L1/TGF-βRII双功能抗体SHR-1701联合EZH2抑制剂SHR2554用于治疗既往接受过治疗的晚期淋巴瘤和实体瘤患者的I期研究
Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.
讲者：Kaichao Feng, MD | Department of Bio-therapeutic, The First Medical Center, Chinese PLA General Hospital（中国人民解放军总医院第一医学中心 丰恺超）
摘要号：2508
一种针对HER2的新型三特异性NK细胞衔接器疗法用于晚期实体瘤患者的1/2期研究： DF1001单药治疗1期剂量递增结果
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.
讲者：Howard Safran, MD | Brown University School of Medicine-Rhode Island Hospital
临床科学研讨会 （Clinical Science Symposium）
摘要号：2509
免疫检查点抑制剂诱导的自身免疫性糖尿病相关的临床和免疫表型
Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.
讲者: Karina Nicole Ruiz-Esteves, MD | Massachusetts General Hospital
摘要号：2510
粪便微生物群移植治疗免疫性结肠炎的一线治疗
First-line treatment of fecal microbiota transplantation for immune-mediated colitis.
讲者：Yinghong Wang, MD, PhD, MS | University of Texas MD Anderson Cancer Center
摘要号：2511
在免疫检查点治疗引起的心肌炎和肌炎患者中确定合理免疫抑制策略的分子靶点
Identifying molecular targets for rational immunosuppressive strategies in patients with immune checkpoint therapy-induced myocarditis and myositis.
讲者：Bilal Ahmed Siddiqui, MD | MD Anderson Cancer Center
（本文依照报告日期和出场排序整理，如有错误或遗漏，敬请留言指正。）
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions?filters=%7B%22track%22:%5B%7B%22key%22:%22Developmental%20Therapeutics%E2%80%94Immunotherapy%22%7D%5D%7D
排版编辑：肿瘤资讯-云初
苏公网安备32059002004080号
